



Statement

Takeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees

Osaka, JAPAN, July 9, 2024 – Takeda Pharmaceutical Company Limited (“Company”) today announced that it completed the issuance of new shares and disposal of treasury shares (“Issuance of Shares”) on July 8, 2024, under the Long-Term Incentive Plan for the Company Group employees outside of Japan.

In addition, the number of new shares originally planned, and other relevant figures, have been changed due to a partial forfeiture of rights granted to previously planned allottees, as outlined below.

For details about the Issuance of Shares, please refer to the announcement dated June 11, 2024, “Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan”.

1. Changes in Outline of Issuance of Shares (Changes are underlined)

	After the change	Before the change
(1) Payment date	July 8, 2024	July 8, 2024
(2) Type and number of shares to be issued and disposed of	<u>15,846,346</u> ordinary shares of the Company, which is the total of the following: (i) <u>8,518,884</u> new shares; and (ii) 7,327,462 treasury shares.	<u>15,905,936</u> ordinary shares of the Company, which is the total of the following: (i) <u>8,578,474</u> new shares; and (ii) 7,327,462 treasury shares.
(3) Issuance and disposal price	4,241 yen per share	4,241 yen per share
(4) Total value of shares to be issued and disposed of	<u>67,204,353,386</u> yen	<u>67,457,074,576</u> yen
(5) Planned allottee	Employees of the Company and the Company’s subsidiaries; numbering <u>10,891</u> persons: <u>15,846,346</u> shares	Employees of the Company and the Company’s subsidiaries; numbering <u>10,954</u> persons: <u>15,905,936</u> shares

2. Reason for the Change

The differences between the planned and actual numbers of new shares and other relevant figures are due to the forfeiture of part or all of the rights granted to the allottees as previously planned at the time of the decision on the Issuance of Shares.

3. Outlook

The above changes will have immaterial impact on the full-year financials for the Company's fiscal year ending on March 31, 2025.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.

For more information, visit www.takeda.com.

Contacts

Investor Relations (English)

Christopher O'Reilly
christopher.oreilly@takeda.com
+81 (0) 3-3278-2543

Media Relations

Brendan Jennings
brendan.jennings@takeda.com
+81 (0) 80-2705-8259

Investor Relations (Japanese)

Christopher O'Reilly
takeda.ir.contact@takeda.com
+81 (0) 3-3278-2306